Orthovita, Inc. (NASDAQ: VITA), a novel spine/orthopaedic surgical biomaterials company, is focused on providing progressive bone regeneration and soft tissue healing technologies. The company’s expertise lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Currently, Orthovita has several key commercial product platforms including: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems. For further information, visit the Company’s web site at www.orthovita.com.
- 17 years ago
QualityStocks
Orthovita, Inc. (NASDAQ: VITA)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…